Destiny Pharma plc
Solution Type
Microbial Management, Antimicrobial Compound
Pathogens Addressed
Bacteria, Viruses
Sectors Served
Human Health
Overview
Destiny Pharma is a Brighton-based clinical-stage biotechnology company developing novel infection prevention medicines. Its lead programs include XF-73 nasal gel for prevention of post-surgical staphylococcal infections including MRSA, and NTCD-M3, a biotherapeutic for preventing recurrent C. difficile infections. In 2024, the company entered administration after failing to secure a licensing partner for its lead candidate.
Stay Updated
Stay connected so that you don't miss the latest AMR insights and updates.
